Clinical trials: Proteinuria, open to volunteers
IgA Nephropathy
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient…
- Trial name
- NCT07541287
- Testing
- JADE101
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Jade Biosciences, Inc.
Diabetic Kidney Disease
Oxygen Therapy in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is the most significant cause of end-stage kidney disease (ESKD). Albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (DN).
- Trial name
- NCT06959485
- Testing
- Oxygen Therapy
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Henoch Schönlein Purpura Nephritis
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease.
- Trial name
- FICHSPN (NCT07315191)
- Testing
- ACEI / ARB+finerenone, ACEI/ARB
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Capital Institute of Pediatrics, China
Albuminuria, Type 2 Diabetes Mellitus (T2DM)
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, for the early regression of albuminuria in…
- Conditions
- Albuminuria, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Diseases
- Trial name
- NCT07667517
- Testing
- Finerenone (BAY 94-8862)
- Where
- 13 sites in China
- Volunteers
- 148 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Proteinuria
Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients
This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either…
- Trial name
- NCT07358520
- Testing
- Huaier Granule, Anlotinib and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
IgA Nephropathy
Study of BHV-1400 in IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
- Trial name
- NCT07054684
- Testing
- BHV-1400
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Biohaven Therapeutics Ltd.
Referral and Consultation, Glomerulonephritis
Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in…
- Conditions
- Referral and Consultation, Glomerulonephritis, Hematuria, Proteinuria
- Trial name
- NCT07431931
- Testing
- Electronic Health Record alert
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Geisinger Clinic
Kidney Transplant; Complications
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs).
- Trial name
- NCT06059664
- Testing
- Finerenone Oral Tablet
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Pediatric Hereditary Kidney Diseases
The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children
This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children
- Trial name
- NCT06890143
- Testing
- Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Children's Hospital of Fudan University
Type 2 Diabetes, Proteinuria
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include: 1.
- Conditions
- Type 2 Diabetes, Proteinuria, Stress, Nephropathy
- Trial name
- iCARE (NCT02818192)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of Manitoba
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Chronic Kidney Diseases, Type 2 Diabetes Mellitus
Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa
Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA).
- Conditions
- Chronic Kidney Diseases, Type 2 Diabetes Mellitus, Arterial Hypertension, Obesity
- Trial name
- RenalTWO (NCT05881447)
- Where
- Tanzania
- Volunteers
- 1,200 people
- Sponsor
- Swiss Tropical & Public Health Institute
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Chronic Kidney Diseases
Role of Coenzyme Q10 in Chronic Kidney Disease
This randomized placebo controlled double blind parallel clinical study will be conducted on 44 non-dialysis chronic kidney disease (CKD) patients (Stages 2-3b).Clinical Study Evaluating the Role of Coenzyme Q10 as Adjuvant…
- Trial name
- NCT05942027
- Testing
- Co-Enzyme Q10
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
IC-MPGN
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative…
- Trial name
- APPARENT (NCT05755386)
- Testing
- iptacopan
- Where
- 131 sites in United States, Argentina and 21 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, Type 2 Diabetes
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes…
- Trial name
- NCT07605390
- Testing
- Epic-Based Clinician Notification, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Baylor Research Institute
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
Sickle cell anemia (SCA) is an inherited red blood disorder. The kidneys are among the most commonly affected organ systems in SCA.
- Trial name
- EMPA-CKD (NCT07175051)
- Testing
- Empagliflozin (oral)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois at Chicago
Hypertension, Left Ventricular Hypertrophy
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric…
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation
- Trial name
- PHRASE (NCT04752293)
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Nephropathy, Diabetic Nephropathies
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes.
- Conditions
- Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1, Albuminuria
- Trial name
- PLUTO (NCT06147232)
- Testing
- Sotagliflozin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Steno Diabetes Center Copenhagen